The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Open accessAbstract
BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paxlovid was shown to be highly effective at preventing progression to severe COVID-19 in symptomatic patients105.”
From Advances in covalent drug discovery (2022) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033
Cited by
Sorted by citations
Items 701–800 of 1,002
Preiss, A., Bhatia, A., Aragon, L., Baratta, J. M., Baskaran, M., Blanceró, F., Brannock, D., Chew, R., Diaz, I. M., Fitzgerald, M., et al. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004711 · Cited by 11
Okabe, A., Carney, D. W., Tawada, M., Akther, T., Aida, J., Takagi, T., Dougan, D. R., Leffler, A. E., Bell, J. A., Frye, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01199 · Cited by 11
Use of Influenza Antivirals in Pandemic Response
Zambon, M. C. F. A., Myles, P. R., & Sugaya, N. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf307 · Cited by 11
Gandolfini, I., Crespo, M., Hellemans, R., Maggiore, U., Mariat, C., Mjøen, G., Oniscu, G. C., Peruzzi, L., Sever, M. Ş., Watschinger, B., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac203 · Cited by 11
Martins‐Filho, P. R., do Nascimento-Júnior, E. M., Alves, J. A. B., Fakhouri, R., & Ferreira, L. C. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03380-5 · Cited by 11
Ho, H. P. T., Vo, D. N. K., Lin, T., Hung, J.-N., Chiu, Y.-H., & Tsai, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113766 · Cited by 11
Detection of Covid-19 Outbreaks Using Built Environment Testing for SARS-CoV-2
Fralick, M., Nott, C., Moggridge, J. A., Castellani, L., Raudanskis, A., Guttman, D. S., Hinz, A. J., Thampi, N., Wong, A., Manuel, D. G., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200203 · Cited by 11
Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review
Kandula, U. R., Tuji, T. S., Gudeta, D. B., Leta, K., Abdulwahed, A., Diriba, K., & Abbas, A. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s397722 · Cited by 11
Ignacio, R. B., Chew, K. W., Moser, C., Currier, J. S., Eron, J. J., Javan, A. C., Giganti, M. J., Aga, E., Gibbs, M. R. J., Kouekam, H. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10039 · Cited by 12
Ko, J. Y., Pham, H., Anglin, O., Chai, S. J., Alden, N. B., Meek, J. I., Anderson, E. J., Weigel, A., Kohrman, A., Lynfield, R., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad266 · Cited by 11
Zhuang, W., Xu, J., Wu, Y., Yang, J., Lin, X., Liao, Y., Wan, J., Weng, L., & Lin, W. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15783 · Cited by 11
Metformin as a potential treatment for COVID-19
McCarthy, M. W. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2215385 · Cited by 11
Neurological side effects and drug interactions of antiviral compounds against SARS‐CoV‐2
Akhvlediani, T., Bernard‐Valnet, R., Dias, S. P., Eikeland, R., Pfausler, B., & Sellner, J. (2023) · European Journal of Neurology · doi:10.1111/ene.16017 · Cited by 11
Jorgensen, P. E. W., Ibarra, J. M., García, C. D., Peris, J., & Llenas‐García, J. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.09.025 · Cited by 11
Buchynskyi, M., Oksenych, V., Kamyshna, I. I., & Kamyshnyi, O. (2024) · Viruses · doi:10.3390/v16010112 · Cited by 11
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Paltra, S., & Conrad, T. (2024) · Advances in respiratory medicine · doi:10.3390/arm92010009 · Cited by 11
Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system
Malden, D. E., McLaughlin, J. M., Hong, V. X., Lewnard, J. A., Ackerson, B. K., Puzniak, L., Kim, J. S., Takhar, H. S., Frankland, T. B., Slezak, J. M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57633-7 · Cited by 11
Cha-Silva, A. S., Gavaghan, M. B., Bergroth, T., Alexander-Parrish, R., Yang, J., Draica, F., Patel, J., Garner, D. A., Stanford, R. H., Meier, G., et al. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001744 · Cited by 11
Karolyi, M., Gruebl, A., Omid, S., Saak, M., Pawelka, E., Hoepler, W., Kelani, H., Kuran, A., Laferl, H., Ott, C., et al. (2022) · Infection · doi:10.1007/s15010-022-01915-7 · Cited by 11
Gomaa, A. A., Abdel-Wadood, Y. A., & Gomaa, M. A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01062-3 · Cited by 11
Lasagna, A., Cassaniti, I., Lilleri, D., Quaccini, M., Ferrari, A., Sacchi, P., Bruno, R., Baldanti, F., & Pedrazzoli, P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1036473 · Cited by 11
Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
Esposito, R., Mirra, D., Sportiello, L., Spaziano, G., & D’Agostino, B. (2022) · Biomedicines · doi:10.3390/biomedicines10112815 · Cited by 12
Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populationsPreprint
Sedova, M., Jaroszewski, L., Iyer, M., & Godzik, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.27.493798 · Cited by 11
Lemaitre, F. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01158-7 · Cited by 11
Vadlamudi, N. K., Basham, C. A., Johnston, J. C., Khan, F. A., Migliori, G. B., Centis, R., D’Ambrosio, L., Jassat, W., Davies, M., Schwartzman, K., et al. (2022) · Value in Health · doi:10.1016/j.jval.2023.03.178 · Cited by 11
Sripongpun, P., Pinpathomrat, N., Bruminhent, J., & Kaewdech, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.924454 · Cited by 10
Li, H., Xiang, H., He, B., Zhang, Q., & Peng, W. (2023) · Journal of Global Health · doi:10.7189/jogh.13.06032 · Cited by 10
Clinical Manifestations and Outcomes of Older Patients with COVID-19: A Comprehensive Review
Lee, J. E., Kang, D. H., Kim, S.-Y., Kim, D. K., & Lee, S. (2024) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2023.0157 · Cited by 10
Zhou, J., Zhang, H., Chen, H., Zhang, G., Mao, J., Zhang, T., Tang, Y., Yan, W., Li, C., Ding, Y., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00539-24 · Cited by 10
Lin, G., Wei, Y., Wang, H., Boyer, C., Jia, K. M., Hung, C. T., Jiang, X., Li, C., Yam, C. H. K., Chow, T. Y., et al. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00224-8 · Cited by 10
Wang, H., Cui, G., Cheng, M., Aji, T., Li, G., Hu, X., Li, G., Zhang, S., Zhang, Y., Diao, L., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02126-w · Cited by 10
Inoue, A., Ichikawa, T., Wada, D., Maruyama, S., Shimazu, H., Kashihara, M., Okuda, K., Saito, F., Fukuhara, T., & Nakamori, Y. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106118 · Cited by 10
Yu, W., Krishnan, M. K., Weekly, M., Shanker, R. M., Doshi, P., Ragan, J. A., Greene, R. A., Gampper, B., Caron, S., Mckillop, A., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00798-7 · Cited by 10
Esmaeili, S., Owens, K. L., de León, U. A.-P., Standing, J. F., Lowe, D. M., Zhang, S., Watson, J. A., Schilling, W. H., Wagoner, J., Polyak, S. J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192052 · Cited by 10
The Advances of Broad-Spectrum and Hot Anti-Coronavirus Drugs
Zeng, S., Li, Y., Zhu, W., Luo, Z., Wu, K., Li, X., Fang, Y., Qin, Y., Chen, W., Li, Z., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10071294 · Cited by 10
Coronavirus Disease-2019 and Implications on the Liver
Campbell, P. T., & Fix, O. K. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.08.003 · Cited by 10
Impact of Paxlovid on international normalized ratio among patients on chronic warfarin therapy
Muse, O., Patell, R. D., Lee, M., Lech, T. K., Guirguis, M., Dodge, L. E., & Zwicker, J. I. (2022) · Blood · doi:10.1182/blood.2022017433 · Cited by 10
Hospital at home treatment with remdesivir for patients with COVID-19: real-life experience
Pereta, I., Morancho, A., López, N., Ibáñez, B., Salas, C. M., Moreno, L., Castells, E., Barta, A., Cubedo, M., Coloma, E., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.011 · Cited by 10
Cordero, C. G., & de Vicente, M. S.-T. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2022-003544 · Cited by 10
Taiwo, B., Chew, K. W., Moser, C., Wohl, D. A., Daar, E. S., Li, J. Z., Greninger, A. L., Bausch, C. L., Luke, T. C., Hoover, K., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad013 · Cited by 10
Gui, H., Zhang, Z., Chen, B., Chen, Y., Wang, Y., Long, Z., Zhu, C., Wang, Y., Cao, Z., & Xie, Q. (2023) · Infectious Diseases of Poverty · doi:10.1186/s40249-023-01057-4 · Cited by 10
Anjani, A., Kumar, S., Rathi, B., & Poonam, P. (2023) · RSC Advances · doi:10.1039/d2ra06834f · Cited by 10
Wamser, R., Pach, S., Arkona, C., Baumgardt, M., Aziz, U. B. A., Hocke, A. C., Wolber, G., & Rademann, J. (2023) · ChemMedChem · doi:10.1002/cmdc.202200635 · Cited by 10
Cordero, C. G., & de Vicente, M. S.-T. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.03.001 · Cited by 10
Anthracyclines inhibit SARS-CoV-2 infection
Wang, Z., Pan, Q., Ma, L., Zhao, J., McIntosh, F. A., Liu, Z., Ding, S., Lin, R., Cen, S., Finzi, A., et al. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199164 · Cited by 10
Shahbazi, S., Shariatpanahi, Z. V., & Shahbazi, E. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102117 · Cited by 10
Yang, F., Tran, T. N.-A., Howerton, E., Boni, M. F., & Servadio, J. L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03025-z · Cited by 10
Papagoras, C., Zioga, N., Papadopoulos, V. P., Gerolymatou, N., Kalavri, E., Bounos, C., Simopoulou, T., Fragoulis, G., Panopoulos, S., Fragiadaki, K., et al. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06769-4 · Cited by 10
Ramos, J. M., Pinargote‐Celorio, H., Llenas‐García, J., Moreno, Ó., González‐Cuello, I., González-de-la-Aleja, P., López, B. M., Reus, S., García, M. J. G., Rodrı́guez, J. C., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1218650 · Cited by 10
Yarovaya, О. I., Filimonov, A. S., Baev, D. S., Borisevich, S. S., Chirkova, V. Y., Zaykovskaya, A. V., Mordvinova, E. D., Belenkaya, S. V., Щербаков, Д. Н., Luzina, O. A., et al. (2023) · New Journal of Chemistry · doi:10.1039/d3nj03598k · Cited by 10
Yoshida, S., Sako, Y., Nikaido, E., Ueda, T., Kozono, I., Ichihashi, Y., Nakahashi, A., Onishi, M., Yamatsu, Y., Kato, T., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00359 · Cited by 10
Repurposing of Rutan showed effective treatment for COVID-19 disease
Salikhov, S. I., Abdurakhmonov, I. Y., Ощепкова, Ю. И., Ziyavitdinov, J. F., Berdiev, N. S., Aisa, H. A., Shen, J., Xu, Y., Xu, H. E., Jiang, X., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1310129 · Cited by 10
Sandin, R., Veenstra, D. L., Vankelegom, M., Dzingina, M. D., Sullivan, S. D., Campbell, D., Ma, C., Harrison, C., Draica, F., Wiemken, T. L., et al. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.12.1290 · Cited by 10
Ren, P., Li, S., Wang, S., Zhang, X., & Bai, F. (2023) · Molecules · doi:10.3390/molecules29010225 · Cited by 10
Haid, S., Matthaei, A., Winkler, M., Sake, S. M., Gunesch, A. P., Milke, V., Köhler, N. M., Rückert, J., Vièyres, G., Kühl, D., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01210-23 · Cited by 10
Standing the test of COVID-19: charting the new frontiers of medicine
Cauchemez, S., Cossu, G., Delzenne, N. M., Elinav, E., Fassin, D., Fischer, A., Härtung, T., Kalra, D., Netea, M. G., Neyts, J. H., et al. (2024) · Frontiers in Science · doi:10.3389/fsci.2024.1236919 · Cited by 12
Okoli, G. N., Askin, N., & Rabbani, R. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3120 · Cited by 10
Mafi, J. N., Vangala, S., Kapral, M. K., Wu, P. E., Cui, M., Romanov, A., & Kahn, K. L. (2025) · JAMA · doi:10.1001/jama.2024.28099 · Cited by 10
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware
Ratain, M. J., & Greenblatt, D. J. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2060 · Cited by 10
Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents
Choi, S., Choi, J. H., & Yun, K. W. (2022) · Korean Journal of Pediatrics · doi:10.3345/cep.2022.00458 · Cited by 10
Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19
Aksak‐Wąs, B., Chober, D., Serwin, K., Scheibe, K., Niścigórska-Olsen, J., Niedźwiedź, A., Dobrowolska, M., Żybul, K., Kubacka, M., Zimoń, A., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s378347 · Cited by 10
Inhibiting the Deubiquitinase UCHL1 Reduces SARS-CoV-2 Viral Uptake by ACE2
Bednash, J. S., Johns, F., Farkas, D., Elhance, A., Adair, J. A., Cress, K., Yount, J. S., Kenney, A. D., Londino, J. D., & Mallampalli, R. K. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0331oc · Cited by 10
Matyugina, E. S., Petushkov, I., Суржиков, С. А., Kezin, V. A., Maslova, A. A., Ivanova, O. N., Smirnova, O. A., Kirillov, I., Тимофеевна, Ф. И., Kulbachinskiy, A. V., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043361 · Cited by 10
Geospatial Disparities in Federal COVID-19 Test-to-Treat Program
Smith, E. R., & Oakley, E. M. (2023) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2023.01.022 · Cited by 10
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
Harris, C. E., Vijenthira, A., Ong, S. Y., Baden, L. R., Hicks, L. K., & Baird, J. H. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390778 · Cited by 10
Yang, S., Tong, Y., Chen, L., & Yu, W. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00077-0 · Cited by 10
COVID-19 therapies: do we see substantial progress?
Matusewicz, L., Golec, M., Czogalla, A., Kuliczkowski, K., Konka, A., Zembala-John, J., & Sikorski, A. F. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00341-9 · Cited by 10
Evidence-Based Recommendations on the Use of Nirmatrelvir/Ritonavir (Paxlovid) for Adults in Ontario
Komorowski, A. S., Tseng, A., Vandersluis, S., Leung, E., Ciccotelli, W. A., Langford, B. J., Andany, N., Razak, F. A., Wadhwa, A., Jüni, P., et al. (2022) · doi:10.47326/ocsat.2022.03.57.1.0 · Cited by 10
Safety and Tolerability of Paxlovid (Nirmatrelvir/Ritonavir) in High-risk Patients
Pesko, B., Deng, A., Chan, J. D., Neme, S., Dhanireddy, S., & Jain, R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac588 · Cited by 10
de Oliveira, V., Ibrahim, M., Sun, X., Hilgenfeld, R., & Shen, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1915291/v1 · Cited by 10
Jittamala, P., Schilling, W. H., Watson, J. A., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P. J., Ekkapongpisit, M., Cruz, C. V., Callery, J. J., et al. (2022) · medRxiv · doi:10.1101/2022.10.17.22281161 · Cited by 10
Panagopoulos, P., Petrakis, V., Trypsianis, G. A., & Papazoglou, D. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2099693 · Cited by 9
Labach, D. S., Kohio, H. P., Tse, E. A., Paparisto, E., Friesen, N. J., Pankovich, J., Bazett, M., & Barr, S. D. (2023) · Biomolecules · doi:10.3390/biom13071095 · Cited by 9
Qu, Y., Su, C., Xiang, Z., Wang, Y., Han, J., Pan, J., & Shen, Z. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106535 · Cited by 9
COVID-19: An Update on the Latest Therapeutic Agents
Loo, K.-Y., Tan, L. T., Law, J. W., Hong, K., Chan, K., & Letchumanan, V. (2023) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.0000329 · Cited by 9
Bai, F., Beringheli, T., Vitaletti, V., Santoro, A., Molà, F., Copes, A., Gemignani, N., Pettenuzzo, S., Castoldi, R., Varisco, B., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00994-3 · Cited by 9
Zhou, Y., Feng, W., Yang, C., Wei, X., Fan, L., Wu, Y., Gao, X., Shen, X., Zhang, Z., & Zhao, J. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29891 · Cited by 9
Singleton, J. B., Wang, D., Louis, S., Smith, D. J., Lambrou, A. S., Beekmann, S. E., Midgley, C. M., Polgreen, P. M., Garg, S., Ricaldi, J. N., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae666 · Cited by 9
Wang, W., Zhou, X., Li, W., Zeng, P., Guo, L., Wang, Q., & Li, J. (2025) · Communications Biology · doi:10.1038/s42003-025-07929-9 · Cited by 9
Lemieux, G., Pérez‐Vargas, J., Désilets, A., Hassanzadeh, M., Thompson, C. A. H., Gravel-Trudeau, A., Joushomme, A., Ennis, S., Villanueva, I., Marouseau, É., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02468 · Cited by 9
Laczi, D., Huamán, S. S., Andrews-Clark, T., Laidlaw, S. M., Salah, E., Dumjahn, L., Lukacik, P., Choudhry, H., Walsh, M. A., Carroll, M. W., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117603 · Cited by 9
Deschenes, N. M., Pérez‐Vargas, J., Zhong, Z., Thomas, M. A., Kenward, C., Mosimann, W. A., Worrall, L. J., Waglechner, N., Li, A. X., Maguire, F., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf294 · Cited by 9
Baniecki, M. L., Guan, S., Rai, D. K., Yang, Q., Lee, J. T., Li, H., Weinstein, E. A., Hyde, C. L., Cardin, R. D., Soares, H. D., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105819 · Cited by 9
Self-citationZhou, Y., Gammeltoft, K. A., Tjørnelund, H. D., Ryberg, L. A., Offersgaard, A., Czarnota, A., Duan, Z., Pham, L. V., Fahnøe, U., Peters, G. H. J., et al. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2552716 · Cited by 9
Shumaker, A. H., Bhimraj, A., Bedimo, R. G., Cheng, V. C., Chew, K. W., Daar, E. S., Glidden, D. V., Shafer, R. W., Tien, P. C., Baden, L. R., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf680 · Cited by 9
Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir
(2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2022.000008 · Cited by 9
In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19
Wang, S., Fang, X., & Wang, Y. (2022) · Molecules · doi:10.3390/molecules27134210 · Cited by 9
Optimal COVID-19 therapeutic candidate discovery using the CANDO platform
Mangione, W., Falls, Z., & Samudrala, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970494 · Cited by 9
Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
Liu, Y., Ge, L., Fan, S., Xu, A., Wang, X., Dong, X., Xu, M., Fan, W., Zhong, W., & Liang, X.-S. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00716-7 · Cited by 9
Kane, A. M., Keenan, E. M., Lee, K., Hartkopf, K. J., Ludwig, T., Trapskin, P. J., Vanderloo, J. P., & Schulz, L. T. (2022) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1729 · Cited by 9
Park, J. J., Lee, J., Seo, Y. B., & Na, S. H. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0123 · Cited by 9
Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice
Enomoto, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315027 · Cited by 9
Treating asthma in the time of COVID
Carr, T. F., Fajt, M. L., Kraft, M., Phipatanakul, W., Szefler, S. J., Zeki, A. A., Peden, D. B., & White, S. R. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.12.800 · Cited by 9
Tadmor, T., Alapi, H., & Rokach, L. (2023) · Blood · doi:10.1182/blood.2022019017 · Cited by 9
Adedayo, A., & Famuti, A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101216 · Cited by 9
Yan, J., Cai, H., Wang, J., Zhu, M., Li, P., Li, P., Wu, B., Che, X., Gu, L., & Mou, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1147980 · Cited by 9
Chawla, A., Birger, R. B., Wan, H. I., Cao, Y., Maas, B. M., Paschke, A. A., Anda, C. S. D., Rizk, M. L., & Stone, J. A. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2895 · Cited by 9
Schneider, J., Wobser, R., Kühn, W., Wagner, D., Tanriver, Y., & Walz, G. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03154-w · Cited by 9
The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials
Thorlund, K., Smith, D. M., Linsell, C., White, N. J., Butler, C., Boulware, D. R., Currier, J. S., Harari, O., Lhomme, E., Wourgaft, N. S., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00281-1 · Cited by 9
COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants
Padasas, B. T., Españo, E., Kim, S., Song, Y., Lee, C., & Kim, J.-K. (2023) · Immune Network · doi:10.4110/in.2023.23.e13 · Cited by 9
Metadata
- Authors
- Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
- Affiliations
- Pfizer (United States) (US)
- From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
- Corresponding author
- Hammond, Jennifer
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-04-14
- Volume
- 386
- Issue
- 15
- Pages
- 1397-1408
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8908851
- OpenAlex
- W4212904481
- Cited by
- 2,323
- References
- 21
- Citations by year
- 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
- FWCI
- 261.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
- MeSH terms
- Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
